---
title: "Sai Parenterals Ltd (SAIPARENT) — Share Price, Financials & Analysis"
symbol: "SAIPARENT"
company: "Sai Parenterals Ltd"
canonical: "https://tapetide.com/stocks/SAIPARENT"
isin: "INE0H9F01037"
nse_symbol: "SAIPARENT"
bse_code: "544742"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 2294.67
generated_at: "2026-09-13T19:36:50.276Z"
---

# Sai Parenterals Ltd (SAIPARENT)

Canonical page: https://tapetide.com/stocks/SAIPARENT

## Company

- **NSE Symbol:** SAIPARENT
- **BSE Code:** 544742
- **ISIN:** INE0H9F01037
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2026-04-02
- **Face Value:** ₹5
- **F&O Eligible:** No
- **Website:** saiparenterals.com

## About

Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]

## Latest Price

- **Price:** ₹523.35
- **Change:** +0.8 (+0.15%)
- **Open:** ₹516.5
- **Day High:** ₹527.9
- **Day Low:** ₹515.55
- **Previous Close:** ₹522.55
- **Volume:** 39054
- **As Of:** 2026-09-11T09:59:58+00:00

## Key Fundamentals

Observed at 2026-09-11T04:34:53.069940Z.

- **Market Cap:** ₹2294.67 Cr
- **Classification:** Microcap
- **P/E (reported):** 111
- **Book Value:** ₹111.09
- **Price to Book:** 4.7
- **Dividend Yield:** 0%
- **ROE:** 2.88%
- **ROCE:** 3.57%
- **Debt to Equity:** 0.96
- **Revenue (yearly):** ₹389.5 Cr
- **Net Income:** ₹14.3 Cr
- **EBITDA:** ₹47.2 Cr
- **52-Week High:** ₹706
- **52-Week Low:** ₹400
- **RSI (14):** 43.63

## Key Insights

### Strengths

- Debtor days have improved from 253 to 173 days.

### Weaknesses

- Company has low interest coverage ratio.
- Company has a low return on equity of 8.64% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 173 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y |
| --- | --- | --- | --- |
| cash flow growth | — | 180.69% | 412.67% |
| ebitda margin growth | -5.86% | -50.41% | -43.15% |
| net income growth | -40.15% | -0.69% | 48% |
| revenue growth | -9.16% | 137.94% | 58% |
| roce | -7.89% | -87.66% | -82.6% |
| roe | -39.82% | -80.88% | 9.65% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- |
| Sales | 33.39 | 96.15 | 197.93 | 178.67 |
| Expenses | 28.65 | 99.71 | 171.83 | 155.15 |
| Operating Profit | 4.74 | -3.56 | 26.1 | 23.52 |
| OPM % | 14.2 | -3.7 | 13.19 | 13.16 |
| Other Income | 1.17 | 3.13 | 2.88 | 3.74 |
| Interest | 2.46 | 5.41 | 8.4 | 9.36 |
| Depreciation | 1.45 | 5.79 | 8.18 | 8.11 |
| Profit before tax | 2 | -11.63 | 12.4 | 9.79 |
| Tax % | 29.5 | -42.65 | -6.13 | 19 |
| Net Profit | 1.42 | -6.66 | 13.16 | 7.92 |
| EPS in Rs | 0.52 | -1.8 | 2.98 | 1.79 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 97 | 154 | 163 | 381 |
| Expenses | 78 | 122 | 124 | 342 |
| Operating Profit | 19 | 32 | 39 | 39 |
| OPM % | 19 | 21 | 24 | 10 |
| Other Income | 0 | 1 | 1 | 9 |
| Interest | 6 | 11 | 12 | 19 |
| Depreciation | 6 | 9 | 8 | 17 |
| Profit before tax | 7 | 13 | 20 | 12 |
| Tax % | 40 | 33 | 28 | -20 |
| Net Profit | 4 | 8 | 14 | 14 |
| EPS in Rs | 6.13 | 6.36 | 5.43 | 3.23 |
| Dividend Payout % | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | 7 | 13 | 13 | 22 |
| Reserves | 24 | 61 | 80 | 469 |
| Borrowings | 69 | 119 | 94 | 469 |
| Other Liabilities | 34 | 75 | 85 | 465 |
| Total Liabilities | 134 | 268 | 272 | 1424 |
| Fixed Assets | 44 | 70 | 53 | 364 |
| CWIP | 2 | 0 | 0 | 212 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 88 | 198 | 219 | 848 |
| Total Assets | 134 | 268 | 272 | 1424 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | -13 | -30 | 33 | 93 |
| Cash from Investing Activity | -19 | -46 | 0 | -274 |
| Cash from Financing Activity | 24 | 79 | -36 | 596 |
| Net Cash Flow | -8 | 2 | -2 | 415 |
| Free Cash Flow | -30 | -72 | 41 | -184 |
| CFO/OP | -54 | -94 | 86 | 253 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Debtor Days | 231 | 302 | 283 | 173 |
| Inventory Days | 83 | 143 | 199 | 259 |
| Days Payable | 140 | 203 | 225 | 224 |
| Cash Conversion Cycle | 174 | 242 | 257 | 208 |
| Working Capital Days | 19 | 72 | 79 | -161 |
| ROCE % | — | 16 | 17 | 5 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- |
| Promoters | 61.23% | 51.16% | 51.16% |
| FIIs | 0% | 5.73% | 4.03% |
| DIIs | 0% | 12.86% | 8.53% |
| Government | 0% | 0% | 0% |
| Public | 0% | 22.67% | 25.33% |
| Others | 38.77% | 7.59% | 10.95% |
| No. of Shareholders | 119 | 143 | 9312 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 2 / 9 / 8

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 521.04 | Buy |
| EMA (10) | 523.86 | Sell |
| SMA (20) | 527.93 | Sell |
| EMA (20) | 529.01 | Sell |
| SMA (50) | 548.77 | Sell |
| EMA (50) | 537.03 | Sell |
| SMA (100) | 537.25 | Sell |
| EMA (100) | 526.09 | Sell |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 44.15 | Neutral |
| MACD (12,26,9) | -7.53 | Buy |
| Stochastic (14,3,3) | 48.99 | Neutral |
| ADX (14) | 23.11 | Neutral |
| Williams %R (14) | -51.62 | Neutral |
| ATR (14) | 18.24 | High Volatility |
| ROC (12) | -1.42 | Sell |
| Stoch RSI (14) | 67.66 | Neutral |
| UO (7,14,28) | 49.77 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd9ef5d4-ad4e-4815-a2cc-83334cf8d5d2.pdf) |
| 2026-09-10 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5432964-e248-4e00-8ff7-5bcfada4e37a.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e5e8109-dd66-401a-9b86-0dd37445f1c1.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d337d291-738c-4639-a55c-068e69158c58.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f74e812-ea70-4761-a181-13d5b67d2a41.pdf) |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0b821ff-6b29-4692-bcc9-14663b391b98.pdf) |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=84af1c15-c5a7-4893-9d74-6ade24c935b2.pdf) |
| 2026-08-19 | [Notice Of 25Th Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=953dea9a-bba9-42d3-a5e2-5b75688cca05.pdf) |
| 2026-08-19 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4df2a73e-7184-46e0-84f1-d290b3c47c56.pdf) |
| 2026-08-19 | [Book Closure Intimation For 25Th Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=927c0f7c-d731-4e63-91c6-c097f1aaa2a7.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef1396a3-8f04-4a00-840a-911a115fdd29.pdf) |
| 2026-05-29 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4fbba2c1-2369-4fda-b147-3d9e8c2c0d54.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4785464d-6066-4864-a20a-123966a24631.pdf) |
| 2026-05-26 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd954b8c-9f12-4ac1-a456-b1ef83214df7.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6599013f-ce8f-48fe-b1b2-b2b30a51207d.pdf) |
| 2026-05-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ca658cc-335e-45d2-a4ed-4986177cf1d1.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-11 | [Financial Results For The Quarter Ended 30.06.2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82c29b2e-6b58-42a9-8567-105832ddb2ab.pdf) |
| 2026-05-23 | [Un Audited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79f5c8ba-0c05-4731-a49f-37f3b071dffc.pdf) |
| 2026-05-23 | [Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31.03.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=416a41cb-e493-4fb4-8696-c08cbbba4611.pdf) |
| 2026-04-22 | [Results-Delay in Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b8bf3aa-aa60-43e9-a475-24a6805095c5.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4fbba2c1-2369-4fda-b147-3d9e8c2c0d54.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4fbba2c1-2369-4fda-b147-3d9e8c2c0d54.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/dd954b8c-9f12-4ac1-a456-b1ef83214df7.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Sai Parenterals delays results submission to 15 May 2026; audited FY26 results due by 30 May 2026. | [Results-Delay in Financial Results 9h - Sai Parenterals delays results submission to 15 May 2026; audited FY26 results due by 30 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8b8bf3aa-aa60-43e9-a475-24a6805095c5.pdf) |
| 6 Apr - Trading window closed from April 2, 2026 for Q3 and FY26 results board meeting. | [Closure of Trading Window 6 Apr - Trading window closed from April 2, 2026 for Q3 and FY26 results board meeting.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d0c4a4a4-4fb3-4da2-b5be-ca5b97a0ed33.pdf) |
| 6 Apr - Sai Parenterals appointed three KMPs as authorised persons under Regulation 30(5). | [Intimation Under Regulation 30(5) Of SEBI 6 Apr - Sai Parenterals appointed three KMPs as authorised persons under Regulation 30(5).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a39da924-c4c9-4064-b2f5-237ac336bbf0.pdf) |
| 2d - Board approved up to AUD 1.75 million loan to Sai Singapore Pte. Ltd. on April 20, 2026. | [Board Meeting Outcome for Outcome Of Board Meeting 2d - Board approved up to AUD 1.75 million loan to Sai Singapore Pte. Ltd. on April 20, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/e138e3bf-de2a-4482-b7de-f467d64491a7.pdf) |
| 22 Apr - Sai Parenterals delays results submission to 15 May 2026; audited FY26 results due by 30 May 2026. | [Results-Delay in Financial Results 22 Apr - Sai Parenterals delays results submission to 15 May 2026; audited FY26 results due by 30 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8b8bf3aa-aa60-43e9-a475-24a6805095c5.pdf) |
| 20 Apr - Board approved up to AUD 1.75 million loan to Sai Singapore Pte. Ltd. on April 20, 2026. | [Board Meeting Outcome for Outcome Of Board Meeting 20 Apr - Board approved up to AUD 1.75 million loan to Sai Singapore Pte. Ltd. on April 20, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e138e3bf-de2a-4482-b7de-f467d64491a7.pdf) |
| 14 Apr - Board meeting on April 20, 2026 to consider investing in or lending to Noumed Pharmaceuticals Pty Limited. | [Board Meeting Intimation for INTIMATION OF BOARD MEETING WHICH IS PROPOSED TO BE HELD ON 20TH OF APRIL 2026 14 Apr - Board meeting on April 20, 2026 to consider investing in or lending to Noumed Pharmaceuticals Pty Limited.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9197d507-464b-492c-8ee7-3dde9c1e5792.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:36:50.276Z.